



Socioeconomic



Population¹

29 651 054 (2024)



Life expectancy at birth²

70 years (2023)



GDP/capita (current US\$)³



US\$ 1447.3 (2024)



Spending on health

Current health expenditure (CHE)/capita (current US\$)⁴

US\$ 88 (2022)





Spending on pharmaceuticals

Government pharmaceutical expenditure⁴

US\$ 72 million

Government pharmaceutical expenditure/capita⁴

US\$ 2.4 (2023)



Medical and pharmacy workforce

Medical doctors/
10 000 population⁶

8.67 (2023)

Pharmacists/
10 000 population⁶

2.23 (2023)

Pharmacy education
accreditation

Yes

Continuing professional
development for pharmacists


Partly



Pharmaceutical legislation and policy

- | | | | |
|------|---|-----------|--|
| 1970 | Drugs Advisory Council and Drugs Advisory Committee Formation Rules, 2037 | 2014 | Codes on sales and distribution |
| 1978 | Drugs Act, 2035; Drug Registration Regulation, 2038 | 2015 | Hospital Pharmacy Guideline |
| 1981 | Narcotic Drugs (Control) Act, 2033 | 2015-2020 | Nepal Health Sector Strategy |
| 1983 | Interrogation and Inspection Regulation, 2040 | 2016 | Codes on Drug Manufacturing; Medicine Registration Guidance |
| 1986 | Drug Standard Regulation, 2043 | 2017 | Health Insurance Act; Special permission guideline; Health Technology Product and Equipment Directive 2074 |
| 1991 | National Health Policy | 2019 | National Health Policy |
| 1995 | National Drug Policy | 2023-2030 | Nepal Health Sector Strategy |
| 2000 | Nepal Pharmacy Council Act, 2057 | 2024 | Codes on Sales and Distribution of medicines |
| | | 2024-2028 | National Action Plan on AMR |
| | | 2033 | Narcotic Drugs (Control) Act |

Intellectual property rights



Rational use and antimicrobial resistance

% of market share of non-EML products

No data

WHO Global Antimicrobial Resistance and Use Surveillance System enrollment⁷: Yes, 2020

Total consumption of antibiotics: 33.27 DDD (2023, Antibacterials)

FDC sales in the private market

No data

Number of antibiotics on the private market

	Total	AWaRe			Not recommended
		Access	Watch	Reserve	
Single drugs	90				
FDCs	37				

Market entry



National Regulatory Authority

Department of Drug Administration (DDA)

Website: <https://www.dda.gov.np/>
Staff: 115 (Technical and non technical)
Annual budget: No data

Products regulated

☒ Medicines⁸ ☒ Biologicals⁸ ☒ Medical devices ☒ Traditional medicines⁸

Licensing of establishments

☒ Manufacturers ☒ Importers ☒ Exporters ☒ Wholesellers ☒ Distributors ☒ Retailers

National Medicines Quality Control Laboratory

1

☒ ISO 17025 certified ☒ WHO prequalified

Body responsible for selection of medical products⁹


Department of Health Services

☒ HTA used in the selection process
☒ NEML incorporated AWaRE list
☒ Medicines listed by level of care
☒ Traditional medicines included

National Essential Medicines List (number of active ingredient)¹⁰



National Medicines Formulary¹⁰



National Essential Diagnostics List¹¹: National Essential In-Vitro Diagnostics List 2024

Rational selection



Purchasing



Public sector

☒ Procurement¹²

Agency responsible for procurement¹³: Federal - Logistic Management Section, Management Division, Department of Health Service, Federal Level Hospital; Province - Province Health Logistics Management Centre; Province Level Hospital; Local - Local level body, Basic Hospital LMIS

LMIS used: Management Division, Department of Health Services

Frequency of tender: No data

Private sector

☒ Social Health Insurance

Name of SHI scheme¹⁴: National Health Insurance Program (NHIP)

Population coverage¹⁵: 15.19%

Number of products covered¹⁶: 1289

Pricing regulation

Pricing regulatory authority⁹

DDA and Drug Price Monitoring Committee

Public sector

Tendering: Yes

Private sector

Maximum retail price¹²: Yes

Number of price controlled products¹⁷: 117

No data

Market distribution



Estimated pharmaceutical market value

No data

Public

Tertiary and secondary hospitals¹⁸: 234

PHC facilities¹⁸: 184

Private

Manufacturers⁹: 184

Importers: 194

Wholesellers/distributors: No data

Retail pharmacies: 30 185

Market exit



Legal provision for

☒ Cancellation of licences of pharmaceutical establishments

☒ Cancellation of marketing authorization of products

☒ Initiating product recalls and withdrawals

References

1. World Bank, DataBank, Health Nutrition and Population Statistics, Nepal, <https://databank.worldbank.org/source/health-nutrition-and-population-statistics>
2. World Bank, Life expectancy at birth, <https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=NP>, accessed 28 August 2025.
3. World Bank, GDP per capita, <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=NP>, accessed 28 August 2025.
4. World Health Organization, Global Health Expenditure database, Current Health Expenditure (CHE) per capita, <https://www.who.int/data/gho>, accessed 15 August 2025.
5. Government of Nepal, Office of the Prime Minister and Council of Ministers, National Statistics Office, Nepal National Living Standards Survey 2022/23, <https://data.nsonline.gov.np/dataset/b6c3c19b-4b15-44bf-8653-1571e76dad14/resource/e2d52301-1c25-498b-8732-4326c62a2372/download/nlss-iv.pdf>, accessed 29 August 2025.
6. World Health Organization, Global Health Observatory, Health Workforce, <https://www.who.int/data/gho/data/themes/topics/health-workforce>, accessed 14 August 2025.
7. Global Antimicrobial Resistance and Use Surveillance System (GLASS) report. Antibiotic use data for 2022. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO, <https://iris.who.int/bitstream/handle/10665/381094/9789240108127-eng.pdf?sequence=1>, accessed 16 August 2025.
8. World Health Organization, Regional Office for South-East Asia, Access to medical products in the South-East Asia Region, 2019, <https://www.who.int/publications/i/item/9789290227281>, accessed 15 August 2025.
9. Government of Nepal, Ministry of Health and Population, Department of Drug Administration, <https://www.dda.gov.np>, accessed 28 August 2025.
10. Government of Nepal, Ministry of Health and Population, Department of Drug Administration, National Formulary 2018, <https://www.dda.gov.np/content/nepalese-national-formulary-nnf>, accessed 28 August 2025.
11. World Health Organization, <https://www.who.int/nepal/news/detail/09-05-2025-nepal-becomes-third-country-to-launch-national-essential-in-vitro-diagnostics-list--upgrades-health-security-infrastructure-with-who-support>, accessed 28 August 2025.
12. World Health Organization, Medicines' price regulatory interventions in the WHO South-East Asia Region: Policy review and recommendations for further research, https://cdn.who.int/media/docs/default-source/searo/hsd/edm/medicines-price-regulatory-interventions-in-the-who-south-east-asia-region-policy-review-and-recommendations-for-further-research.pdf?sfvrsn=5ff3b867_1&download=true, accessed 15 August 2025.
13. Reported by the Ministry of Health and Population, Nepal, 2023 (internal communication)
14. Khanal, Geha N., et al. "Evaluation of the National Health Insurance Program of Nepal: are political promises translated into actions?." *Health research policy and systems* 21.1 (2023): 7.
15. World Health Organization, Regional Office for South-East Asia, Access to medical products in the South-East Asia Region, 2023, <https://iris.who.int/handle/10665/373774>, accessed 15 August 2025.
16. Government of Nepal, Health Insurance Board, <https://hib.gov.np/en/pages/health-care-packages>, accessed 28 August 2025.
17. Poudel, Bhupendra Kumar, and Itsuko Ishii. "Regulation of the price of medicines in developing countries: the case in Nepal." *Journal of Pharmacy Practice and Research* 47.4 (2017): 319-320.
18. Government of Nepal, Ministry of Health and Population, Department of Health Services, Management Division, Integrated Health Information Management System (IHIMS), Nepal Health Fact Sheet, 2024, <http://dohs.gov.np/content/24/nepal-health-fact-sheet-2024/>, accessed 28 August 2025.